Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding

Program Goals

Control Blood Glucose Levels to Prevent or Delay the Onset of Complications

HbA1c = Fasting Blood Glucose and Postprandial Glucose

Type 1 Diabetes Clinical Trial: MKC-171

Study Design

Inhaler Device: Gen2 vs MedTone

Mean Change in HbA1c From Baseline to Week 24

Mean Change in HbA1c Levels From Screening to Week 24

Mean Change in Body Weight From Baseline to Week 24

Adverse Events

Severe Hypoglycemia Event Rates

Cough Over Time

Mean FEV1 From Baseline to Week 24

Type 2 Diabetes Clinical Trial -- MKC-175: Study Design

Average Daily Insulin Dose and Mean Change in HbA1c Level From Baseline to Week 24

Mean 7-Point Glucose Measurements at Baseline and at Week 24

Change in Body Weight From Baseline to Week 24

Most Common Adverse Event and Rates of Hypoglycemic Events

Patients With New-Onset Cough

Mean FEV1 From Baseline to Week 24

Type 2 Diabetes Clinical Trial -- MKC-102: Study Design

Hypoglycemia and Weight Change

Black Box Warning

Closing Comments: Role of Inhaled Insulin

Abbreviations

References

References (cont)

References (cont)